421 related articles for article (PubMed ID: 29503042)
1. Engrafting human regulatory T cells with a flexible modular chimeric antigen receptor technology.
Koristka S; Kegler A; Bergmann R; Arndt C; Feldmann A; Albert S; Cartellieri M; Ehninger A; Ehninger G; Middeke JM; Bornhäuser M; Schmitz M; Pietzsch J; Akgün K; Ziemssen T; Steinbach J; Bachmann MP
J Autoimmun; 2018 Jun; 90():116-131. PubMed ID: 29503042
[TBL] [Abstract][Full Text] [Related]
2. CD137+CD154- Expression As a Regulatory T Cell (Treg)-Specific Activation Signature for Identification and Sorting of Stable Human Tregs from
Nowak A; Lock D; Bacher P; Hohnstein T; Vogt K; Gottfreund J; Giehr P; Polansky JK; Sawitzki B; Kaiser A; Walter J; Scheffold A
Front Immunol; 2018; 9():199. PubMed ID: 29467769
[TBL] [Abstract][Full Text] [Related]
3. T cells engrafted with a UniCAR 28/z outperform UniCAR BB/z-transduced T cells in the face of regulatory T cell-mediated immunosuppression.
Kegler A; Koristka S; Bergmann R; Berndt N; Arndt C; Feldmann A; Hoffmann A; Bornhäuser M; Schmitz M; Bachmann MP
Oncoimmunology; 2019; 8(9):e1621676. PubMed ID: 31428518
[TBL] [Abstract][Full Text] [Related]
4. Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes.
Tenspolde M; Zimmermann K; Weber LC; Hapke M; Lieber M; Dywicki J; Frenzel A; Hust M; Galla M; Buitrago-Molina LE; Manns MP; Jaeckel E; Hardtke-Wolenski M
J Autoimmun; 2019 Sep; 103():102289. PubMed ID: 31176558
[TBL] [Abstract][Full Text] [Related]
5. Chimeric Antigen Receptor (CAR) Treg: A Promising Approach to Inducing Immunological Tolerance.
Zhang Q; Lu W; Liang CL; Chen Y; Liu H; Qiu F; Dai Z
Front Immunol; 2018; 9():2359. PubMed ID: 30369931
[TBL] [Abstract][Full Text] [Related]
6. Functional effects of chimeric antigen receptor co-receptor signaling domains in human regulatory T cells.
Dawson NAJ; Rosado-Sánchez I; Novakovsky GE; Fung VCW; Huang Q; McIver E; Sun G; Gillies J; Speck M; Orban PC; Mojibian M; Levings MK
Sci Transl Med; 2020 Aug; 12(557):. PubMed ID: 32817364
[TBL] [Abstract][Full Text] [Related]
7. "UniCAR"-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells.
Mitwasi N; Feldmann A; Arndt C; Koristka S; Berndt N; Jureczek J; Loureiro LR; Bergmann R; Máthé D; Hegedüs N; Kovács T; Zhang C; Oberoi P; Jäger E; Seliger B; Rössig C; Temme A; Eitler J; Tonn T; Schmitz M; Hassel JC; Jäger D; Wels WS; Bachmann M
Sci Rep; 2020 Feb; 10(1):2141. PubMed ID: 32034289
[TBL] [Abstract][Full Text] [Related]
8. Preventing Lck Activation in CAR T Cells Confers Treg Resistance but Requires 4-1BB Signaling for Them to Persist and Treat Solid Tumors in Nonlymphodepleted Hosts.
Suryadevara CM; Desai R; Farber SH; Choi BD; Swartz AM; Shen SH; Gedeon PC; Snyder DJ; Herndon JE; Healy P; Reap EA; Archer GE; Fecci PE; Sampson JH; Sanchez-Perez L
Clin Cancer Res; 2019 Jan; 25(1):358-368. PubMed ID: 30425092
[TBL] [Abstract][Full Text] [Related]
9. In Vivo Expansion and Antitumor Activity of Coinfused CD28- and 4-1BB-Engineered CAR-T Cells in Patients with B Cell Leukemia.
Cheng Z; Wei R; Ma Q; Shi L; He F; Shi Z; Jin T; Xie R; Wei B; Chen J; Fang H; Han X; Rohrs JA; Bryson P; Liu Y; Li QJ; Zhu B; Wang P
Mol Ther; 2018 Apr; 26(4):976-985. PubMed ID: 29503204
[TBL] [Abstract][Full Text] [Related]
10. The Future of Regulatory T Cell Therapy: Promises and Challenges of Implementing CAR Technology.
Mohseni YR; Tung SL; Dudreuilh C; Lechler RI; Fruhwirth GO; Lombardi G
Front Immunol; 2020; 11():1608. PubMed ID: 32793236
[TBL] [Abstract][Full Text] [Related]
11. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB).
Song DG; Ye Q; Carpenito C; Poussin M; Wang LP; Ji C; Figini M; June CH; Coukos G; Powell DJ
Cancer Res; 2011 Jul; 71(13):4617-27. PubMed ID: 21546571
[TBL] [Abstract][Full Text] [Related]
12. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.
Milone MC; Fish JD; Carpenito C; Carroll RG; Binder GK; Teachey D; Samanta M; Lakhal M; Gloss B; Danet-Desnoyers G; Campana D; Riley JL; Grupp SA; June CH
Mol Ther; 2009 Aug; 17(8):1453-64. PubMed ID: 19384291
[TBL] [Abstract][Full Text] [Related]
13. Transient mTOR inhibition rescues 4-1BB CAR-Tregs from tonic signal-induced dysfunction.
Lamarthée B; Marchal A; Charbonnier S; Blein T; Leon J; Martin E; Rabaux L; Vogt K; Titeux M; Delville M; Vinçon H; Six E; Pallet N; Michonneau D; Anglicheau D; Legendre C; Taupin JL; Nemazanyy I; Sawitzki B; Latour S; Cavazzana M; André I; Zuber J
Nat Commun; 2021 Nov; 12(1):6446. PubMed ID: 34750385
[TBL] [Abstract][Full Text] [Related]
14. Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function.
Salter AI; Ivey RG; Kennedy JJ; Voillet V; Rajan A; Alderman EJ; Voytovich UJ; Lin C; Sommermeyer D; Liu L; Whiteaker JR; Gottardo R; Paulovich AG; Riddell SR
Sci Signal; 2018 Aug; 11(544):. PubMed ID: 30131370
[TBL] [Abstract][Full Text] [Related]
15. Precision Engineering of an Anti-HLA-A2 Chimeric Antigen Receptor in Regulatory T Cells for Transplant Immune Tolerance.
Muller YD; Ferreira LMR; Ronin E; Ho P; Nguyen V; Faleo G; Zhou Y; Lee K; Leung KK; Skartsis N; Kaul AM; Mulder A; Claas FHJ; Wells JA; Bluestone JA; Tang Q
Front Immunol; 2021; 12():686439. PubMed ID: 34616392
[TBL] [Abstract][Full Text] [Related]
16. CD4
Fu RY; Chen AC; Lyle MJ; Chen CY; Liu CL; Miao CH
Cell Immunol; 2020 Dec; 358():104216. PubMed ID: 32987195
[TBL] [Abstract][Full Text] [Related]
17. Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies.
Mamonkin M; Mukherjee M; Srinivasan M; Sharma S; Gomes-Silva D; Mo F; Krenciute G; Orange JS; Brenner MK
Cancer Immunol Res; 2018 Jan; 6(1):47-58. PubMed ID: 29079655
[TBL] [Abstract][Full Text] [Related]
18. Inclusion of 4-1BB Costimulation Enhances Selectivity and Functionality of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells.
Starr R; Aguilar B; Gumber D; Maker M; Huard S; Wang D; Chang WC; Brito A; Chiu V; Ostberg JR; Badie B; Forman SJ; Alizadeh D; Wang LD; Brown CE
Cancer Res Commun; 2023 Jan; 3(1):66-79. PubMed ID: 36968221
[TBL] [Abstract][Full Text] [Related]
19. Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2
Priceman SJ; Tilakawardane D; Jeang B; Aguilar B; Murad JP; Park AK; Chang WC; Ostberg JR; Neman J; Jandial R; Portnow J; Forman SJ; Brown CE
Clin Cancer Res; 2018 Jan; 24(1):95-105. PubMed ID: 29061641
[No Abstract] [Full Text] [Related]
20. The UniCAR system: A modular CAR T cell approach to improve the safety of CAR T cells.
Bachmann M
Immunol Lett; 2019 Jul; 211():13-22. PubMed ID: 31091431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]